Category: GI Dynamics
Regulators in Switzerland and Germany take the 1st steps toward reimbursement for GI Dynamics' flagship EndoBarrier device to treat obesity and Type II diabetes.
GI Dynamics (ASX:GID) said Swiss and German regulators took the 1st steps toward reimbursement in those countries for its EndoBarrier weight loss and diabetes device.
GI Dynamics raises $35 million on its way to the $52 million it's hoping to raise to back a U.S. trial of its EndoBarrier weight loss and diabetes device.
GI Dynamics (ASX:GID) said it's pulled in nearly $35 million as part of a $52 million funding round it's planning to use to back a U.S. trial of its EndoBarrier device.
The Lexington, Mass.-based medical device company said in a regulatory filing that it's drummed up $34.8 million from 13 unnamed investors.
GI Dynamics says it's set to raise about $52 million from a private placement and is looking to drum up another $2.3 million from existing shareholders to back a U.S. trial of its EndoBarrier weight loss device.
GI Dynamics (ASX:GID) said it's raised roughly $52.2 million (A$57.5 million) in a private placement and is offering another $2.3 million (A$2.5 million) in a stock purchase plan for existing shareholders.
French regulators bankroll a study to look at the costs and utility of GI Dynamics' EndoBarrier weight-loss device.
French regulators will fund a trial looking at the cost and utility of the EndoBarrier device for Type II diabetes and weight loss made by GI Dynamics (ASX:GID).
GI Dynamics says another 5 centers in Europe are offering its EndoBarrier weight-loss device for treating obesity and Type II diabetes.
GI Dynamics (ASX:GID) said another 5 medical centers in Europe are online with its EndoBarrier weight loss and diabetes device.
The Lexington, Mass.-based medical device company said centers in Spain, Switzerland and 3 in Germany are now implanting the device, a gut liner designed to inhibit the uptake of nutrients from food.
Weight-loss devices maker GI Dynamics tells investors today that the company may seek new funding as it works to support clinical trials in pursuit of U.S. regulatory approval.
Investors Down Under shied away from weight-loss devices maker GI Dynamics (ASX:GID) today after president & CEO Stuart Randle told shareholders that the company may need to raise new funds in order to support its clinical trials.
Aesthetics giant Allergan wins a panel date with the FDA for review of its Juv[eacute]derm Voluma XC dermal filler.
MASSDEVICE ON CALL — Aesthetic medical device maker Allergan (NYSE:AGN) will get a date with the FDA to review clinical data for the company's Juv[eacute]derm Voluma XC dermal filler.
Allergan hopes to win indication for deep implantation for aesthetic restoration in the face, according to the FDA notice.